ArticleJournal of medical virology2021
Guidelines on newly identified limitations of diagnostic tools for COVID-19 and consequences.
Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Diagnostic value comparative analysis of the commercial kits for the detection of SARS-CoV-2 in clinical samples: a systematic review and meta-analysis.Iranian journal of microbiology · 2025Review
- The interplay of tuberculosis and COVID-19: Insights into global health challenges.Journal of biosciences · 2025Review
- Article
- Article
- An Unusual Presentation of Superior Mesenteric Venous Occlusion in Mild COVID-19.Indian journal of clinical biochemistry : IJCB · 2023Article
- Clinical assessment of SARS-CoV-2 infectivity by rapid antigen test compared with virus isolation.Journal of clinical virology plus · 2023Article
- Article
- Evaluation of the Access Bio CareStart rapid SARS-CoV-2 antigen test in asymptomatic individuals tested at a community mass-testing program in Western Massachusetts.Scientific reports · 2022Article
- A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Possibility of Relapse of COVID19 in Asymptomatic Cases and Risk Assessment.Indian journal of clinical biochemistry : IJCB · 2022Article
- Article
- Vitamin C and its therapeutic potential in the management of COVID19.Clinical nutrition ESPEN · 2022Review
- Toward smart diagnosis of pandemic infectious diseases using wastewater-based epidemiology.Trends in analytical chemistry : TRAC · 2022Review
- Rapid identification of SARS-CoV-2 in the point-of-care using digital PCR-based Dr. PCR™ Di20K COVID-19 Detection Kit without viral RNA extraction.Genes & genomics · 2022Article
- Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology.Clinics in laboratory medicine · 2022Review
- COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections.Frontiers in medicine · 2022Article
- Systematic Approach to Address Early Pandemic's Diagnostic Unmet Needs.Frontiers in microbiology · 2022Article
- Diagnostic evaluation of qRT-PCR-based kit and dPCR-based kit for COVID-19.Genes & genomics · 2021Article
- RNA-extraction-free nano-amplified colorimetric test for point-of-care clinical diagnosis of COVID-19.Nature protocols · 2021Article
- Two cases of acute endocarditis misdiagnosed as COVID-19 infection.Echocardiography (Mount Kisco, N.Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) caused by coronavirus has spread worldwide and has become the deadliest pandemic of the 21st century. Such rapid spread is predominantly attributed to the poor diagnosis and its asymptomatic transmission. In the absence of treatment regime, timely diagnosis is the best available remedy that can restrict its spread. An early diagnosis of COVID-19 is critical for determining the line of treatment and preventing long term complications in the infected subject. Unfortunately, available rapid antigen and antibody kits are known to be erroneous whereas reverse transcription polymerase chain reaction based tests are expensive, viral load dependent and at times inconclusive. In current scenario, the false-negative results imposed a major risk to the individual patient care and also to the efforts for containing the spread at the population level, where as false positives are traumatic for families and can lead to improper treatment resulting in severe complications. In this article, the limitations of available diagnostic procedures have been elaborated and plausible combination approach has been advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.